IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford
BBC came to film IRBM’s Advent GMP facility
The Jenner Institute signs an agreement with Advent to develop a novel coronavirus vaccine
The Jenner Institute, Oxford University, UK and Advent Srl – an IRBM company, Pomezia,Italy - are continuing their long-standing history of collaboration, by announcing today a new agreement to develop a novel vaccine for coronavirus. The Jenner Institute at the…
World Vaccine Congress Washington 2019
Stefania Di Marco, Ph.D., Qualified Person of ADVENT, and Daniel Conlon, IRBM’s VP of Business Development, North America, will be attending the World Vaccine Congress in Washington, D.C. from April 14 to April 17. To learn more about ADVENT’s capabilities,…
World Vaccine Congress Europe 2019
From October 19-21, ADVENT’s Qualified Person, Dr. Stefania di Marco, will attend the World Vaccine Congress Europe 2019 in Barcelona, Spain. She will be joined by Heidi Kingdon Jones, IRBM’s Global VP of Sales and Marketing. To learn more about…
32nd International Conference on Vaccines and Immunization
Pier Giorgio Pacifici, Ph.D., IRBM’s Business Development Manager, and Stefania Di Marco, PhD, QP of ADVENT, will be attending the International Conference on Vaccines and Immunization in Rome on March 21st-22nd. The event unites renowned vaccination and immunology researchers to…